<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03926091</url>
  </required_header>
  <id_info>
    <org_study_id>CLOVER</org_study_id>
    <nct_id>NCT03926091</nct_id>
  </id_info>
  <brief_title>Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer</brief_title>
  <acronym>CLOVER</acronym>
  <official_title>A Prospective, Multisite, Randomized, Open-label Phase III Clinical Trial (CLOVER Study)Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multisite, randomized, open-label Phase III clinical trial (CLOVER
      study) comparing 4 cycles with 6 cycles of TC (docetaxel+cyclophosphamide) adjuvant
      chemotherapy for 1-3 positive lymph node, ER+/HER2- early breast cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While TC (docetaxel+cyclophosphamide) adjuvant chemotherapy is one of the preferred regimens
      for early breast cancer, we have yet to determine the optimum number of cycles for TC
      adjuvant chemotherapy. In this prospective, open-label clinical trial, estrogen receptor
      (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
      patients with 1-3 positive lymph nodes will be randomized into either 4 cycles or 6 cycles of
      TC adjuvant chemotherapy. The safety and efficacy of each group will be assessed through
      disease-free survival (DFS), invasive disease free survival (iDFS), distant disease free
      survival (DDFS), overall survival (OS) and adverse effects (AE) as graded by Common
      Terminology Criteria for Adverse Events (CTCAE) 4.0.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 3, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Arm 1：6 cycles of TC (Docetaxel 75 mg/m^2 ivgtt d1+Cyclophosphamide 600 mg/m^2 iv d1, 21 days per cycle).
Arm 2：4 cycles of TC (Docetaxel 75 mg/m^2 ivgtt d1+Cyclophosphamide 600 mg/m^2 iv d1, 21 days per cycle).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>invasive disease free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distant disease free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse effects</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2172</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>4 cycles of TC adjuvant chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 cycles of TC (Docetaxel 75 mg/m^2 ivgtt d1+Cyclophosphamide 600 mg/m^2 iv d1, 21 days per cycle).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 cycles of TC adjuvant chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 cycles of TC (Docetaxel 75 mg/m^2 ivgtt d1+Cyclophosphamide 600 mg/m^2 iv d1, 21 days per cycle).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel chemotherapy (injection)</description>
    <arm_group_label>4 cycles of TC adjuvant chemotherapy</arm_group_label>
    <arm_group_label>6 cycles of TC adjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide chemotherapy (injection)</description>
    <arm_group_label>4 cycles of TC adjuvant chemotherapy</arm_group_label>
    <arm_group_label>6 cycles of TC adjuvant chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. women aged 18-70 years old;

          2. Patient has localized invasive breast carcinoma with1-3 positive lymph nodes, and is
             ER+/HER2- confirmed by histopathology after early breast cancer surgery（HER2-negative
             breast cancer (based on most recently analyzed biopsy) defined as a negative in situ
             hybridization test or an Immunohistochemistry (IHC) status of 0, 1+ or 2+. If IHC is
             2+, a negative in situ hybridization (Fluorescence in situ hybridization (FISH),
             Chromogenic in situ hybridization (CISH) , or Silver in situ hybridization (SISH))
             test is required by local laboratory testing.), with at least one of the following
             conditions: (1) histological grade III; (2) Ki67 ≥ 30%; (3) progesterone receptor (PR)
             ≤ 20% positive; (4) age less than 35 years; (5) extensive vascular tumor thrombus; (6)
             multigene detection recurrence score (RS) &gt;25;

          3. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;

          4. Has adequate organ function meeting the following criteria: (1) adequate bone marrow
             function: hemoglobin ≥ 90 g/L (no blood transfusion within 14 days); absolute
             neutrophil count ≥ 1.5 x 109 /L; platelet count ≥ 100 * 109 /L; (2)adequate liver and
             kidney function: Alanine Aminotransferase (ALT) ≤ 3×upper limit of normal (ULN),
             Aspartate Aminotransferase (AST) ≤ 3×ULN, Total Bilirubin (TBIL)≤ 1.5×ULN, serum
             creatinine ≤ 1×ULN，and with endogenous creatinine clearance rate of &gt;50 ml/min
             (Cockcroft-Gault formula).

          5. Participants voluntarily joined the study, has signed informed consent before any
             trial related activities are conducted, has good compliance and has agreed to
             follow-up.

        Exclusion Criteria:

          1. Has received neoadjuvant therapy (include chemotherapy, targeted therapy, radiotherapy
             or endocrine therapy）;

          2. Has bilateral breast cancer;

          3. Has previous history of additional malignancy, with the exception of adequately
             treated basal cell carcinoma and cervical carcinoma in situ.

          4. Has metastatic (Stage 4) breast cancer;

          5. Has any &gt;T4 lesion (UICC1987) (with skin involvement, mass adhesion and fixation, and
             inflammatory breast cancer);

          6. Is pregnant, is breast feeding women, or women of childbearing age who cannot practice
             effective contraceptives;

          7. Patients participating in other clinical trials at the same time;

          8. Has severe organ dysfunction (cardiopulmonary liver and kidney) insufficiency, left
             ventricular ejection fraction (LVEF) &lt; 50% (cardiac ultrasound); severe cardio
             cerebral vascular disease within the 6 months previous of randomization (such as
             unstable angina, chronic heart failure, uncontrolled hypertension with blood
             pressure&gt;150/90mmgh, myocardial infarction, or cerebral blood vessel); diabetic
             patients with poor blood glucose control; patients with severe hypertension;

          9. Has known allergy to taxane and excipients.

         10. Has severe or uncontrolled infection;

         11. Has a history of psychotropic substance abuse and were unable to abandon drug habits,
             or those with history of mental disorders;

         12. the researchers judged patients to be unsuitable for the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhimin Shao, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhimin Shao, MD, PhD</last_name>
    <phone>+86-021-64175590</phone>
    <phone_ext>8808</phone_ext>
    <email>zhimingshao@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chongqing Cancer Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaohua Zeng, M.D.</last_name>
      <phone>+86-023-65311341</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chuangui Song, M.D,</last_name>
      <phone>+86-591-83357896</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yet-Sen Memorial Hospital, Sun Yet-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiang Liu, M.D.</last_name>
      <phone>+86-020-81332199</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhigao Li, M.D.</last_name>
      <phone>+86-451-86298000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Bethune Hospital of Jilin University (The First Hospital of Jilin University)</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhimin Fan, M.D.</last_name>
      <phone>+86-431-88782222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <zip>116027</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Man Li, M.D.</last_name>
      <phone>+86-411-84671291</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng Jin, M.D.</last_name>
      <phone>+86-024-83283333</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haibo Wang, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>OB/GYN Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kejin Wu, M.D.</last_name>
      <phone>+86-021-33189900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhimin Shao, M.D.</last_name>
      <phone>+86-021-64175590</phone>
      <phone_ext>8808</phone_ext>
      <email>zhimingshao@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Zhang, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, ZheJiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peifen Fu, M.D.</last_name>
      <email>zdyy6616@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongjian Yang, M.D.</last_name>
      <phone>+86-571-88122222</phone>
      <email>zjszlyy@zjcc.org.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hanzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Huang, M.D.</last_name>
      <phone>+86-571-87783777</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 31, 2019</study_first_submitted>
  <study_first_submitted_qc>April 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2019</study_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhimin Shao</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <keyword>docetaxel</keyword>
  <keyword>cyclophosphamide</keyword>
  <keyword>adjuvant chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

